Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574779 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
A Phase 2 study, sponsored by Tesaro.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT03574779 is a Phase 2 study that has completed, run by Tesaro. The registered enrollment target is 77 participants.
The verdict
NCT03574779, a Phase 2 study, has completed, sponsored by Tesaro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- DRUG Niraparib
- BIOLOGICAL TSR-042
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03574779
The ClinicalTrials.gov registry entry for NCT03574779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03574779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03574779 about?
NCT03574779 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer". This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovari...
What is the current status of trial NCT03574779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2018-11-15. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT03574779?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Niraparib (DRUG), TSR-042 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03574779?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.